The Experts below are selected from a list of 4047 Experts worldwide ranked by ideXlab platform
Charles M Morin - One of the best experts on this subject based on the ideXlab platform.
-
a german version of the Insomnia Severity Index
Somnologie, 2018Co-Authors: Arne Dieck, Charles M Morin, Jutta BackhausAbstract:Background Insomnia is a prevalent disorder. There is a need for brief, easily manageable, and valid questionnaires to support practitioners in the clinical evaluation of Insomnia.
-
Treatment Agreement, Adherence, and Outcome in Cognitive Behavioral Treatments for Insomnia
Journal of Consulting and Clinical Psychology, 2017Co-Authors: Lu Dong, Charles M Morin, Lynda Belanger, Adriane M. Soehner, Allison G. HarveyAbstract:BACKGROUND: Patient adherence has been identified as an important barrier to the implementation of evidence-based psychological treatments. OBJECTIVE: In cognitive behavioral treatments (CBT) for Insomnia, the current study examined (a) the validity of therapist ratings of patient agreement and adherence against an established behavioral measure of adherence, and (b) the relationship between treatment agreement, adherence, and outcome. METHOD: Participants were 188 adults meeting DSM-IV-TR criteria for chronic Insomnia who were randomized to receive behavior therapy, cognitive therapy, or CBT for Insomnia. Treatment agreement/adherence was measured by (a) weekly therapist ratings of patient agreement and homework completion, and (b) adherence to behavioral strategies (ABS) derived from patient-reported sleep diary. Outcome measures were Insomnia Severity Index and Insomnia remission (Insomnia Severity Index
-
effects of suvorexant on the Insomnia Severity Index in patients with Insomnia analysis of pooled phase 3 data
Sleep Medicine, 2017Co-Authors: Joseph W Herring, Charles M Morin, Ellen Snyder, Duane B. Snavely, Christopher Lines, Kathryn M Connor, David MichelsonAbstract:Abstract Objective Suvorexant is an orexin receptor antagonist that is approved in the US, Japan and Australia for the treatment of Insomnia. Using outcomes from the Insomnia Severity Index (ISI) in the core registration studies, we explored suvorexant effects on sleep problems and their impact on daytime function. Methods Data were pooled from two similar Phase 3, randomized, double-blind, placebo-controlled, parallel-group, three-month trials in elderly (≥65 years) and non-elderly (18–64 years old) Insomnia patients. Age-adjusted (non-elderly/elderly) dose-regimes of 40/30 mg and 20/15 mg were evaluated. The ISI, a 7-item self-rated questionnaire with each item rated on 0–4 scale (higher score corresponds to increasing Severity), was administered to patients as an exploratory assessment in both studies at baseline and one and three months after randomization. Results The analysis included 1824 patients. Suvorexant improved change-from-baseline ISI total scores to a greater extent than placebo (Month three: 20/15 mg = −6.2, 40/30 mg = −6.7, placebo = −4.9, p-values for both active arms vs. placebo Conclusions Suvorexant 20/15 mg and 40/30 mg improved sleep to a greater extent than placebo as assessed by the ISI in patients with Insomnia. Improvement in sleep onset/maintenance as well as a reduction of the impact of sleep problems on daytime function contributed to the overall improvement observed in ISI total score. ClinicalTrials.gov identifier NCT01097616, NCT01097629.
-
Effect of a Web-Based Cognitive Behavior Therapy for Insomnia Intervention With 1-Year Follow-up: A Randomized Clinical Trial.
JAMA Psychiatry, 2017Co-Authors: Lee M Ritterband, Frances P Thorndike, Karen S. Ingersoll, Holly R. Lord, Linda Gonder-frederick, Christina Frederick, Mark Quigg, Wendy F. Cohn, Charles M MorinAbstract:Importance Although cognitive behavior therapy for Insomnia (CBT-I) has been established as the first-line recommendation for the millions of adults with chronic Insomnia, there is a paucity of trained clinicians to deliver this much needed treatment. Internet-delivered CBT-I has shown promise as a method to overcome this obstacle; however, the long-term effectiveness has not been proven in a representative sample with chronic Insomnia. Objective To evaluate a web-based, automated CBT-I intervention to improve Insomnia in the short term (9 weeks) and long term (1 year). Design, Setting, and Participants A randomized clinical trial comparing the internet CBT-I with internet patient education at baseline, 9 weeks, 6 months, and 1 year. Altogether, 303 adults with chronic Insomnia self-referred to participate, of whom 151 (49.8%) reported at least 1 medical or psychiatric comorbidity. Interventions The internet CBT-I (Sleep Healthy Using the Internet [SHUTi]) was a 6-week fully automated, interactive, and tailored web-based program that incorporated the primary tenets of face-to-face CBT-I. The online patient education program provided nontailored and fixed online information about Insomnia. Main Outcomes and Measures The primary sleep outcomes were self-reported online ratings of Insomnia Severity (Insomnia Severity Index) and online sleep diary–derived values for sleep-onset latency and wake after sleep onset, collected prospectively for 10 days at each assessment period. The secondary sleep outcomes included sleep efficiency, number of awakenings, sleep quality, and total sleep time. Results Among 303 participants, the mean (SD) age was 43.28 (11.59) years, and 71.9% (218 of 303) were female. Of these, 151 were randomized to the SHUTi group and 152 to the online patient education group. Results of the 3 primary sleep outcomes showed that the overall group × time interaction was significant for all variables, favoring the SHUTi group (Insomnia Severity Index [ F 3,1063 = 20.65, P F 3,1042 = 6.01, P F 3,1042 = 12.68, P d = 0.79 [95% CI, 0.55-1.04] to d = 1.90 [95% CI, 1.62-2.18]). Treatment effects were maintained at the 1-year follow-up (SHUTi Insomnia Severity Index d = 2.32 [95% CI, 2.01-2.63], sleep-onset latency d = 1.41 [95% CI, 1.15-1.68], and wake after sleep onset d = 0.95 [95% CI, 0.70-1.21]), with 56.6% (69 of 122) achieving remission status and 69.7% (85 of 122) deemed treatment responders at 1 year based on Insomnia Severity Index data. All secondary sleep outcomes, except total sleep time, also showed significant overall group × time interactions, favoring the SHUTi group. Conclusions and Relevance Given its efficacy and availability, internet-delivered CBT-I may have a key role in the dissemination of effective behavioral treatments for Insomnia. Trial Registration clinicaltrials.gov Identifier:NCT01438697
-
validating the cross cultural factor structure and invariance property of the Insomnia Severity Index evidence based on ordinal efa and cfa
Sleep Medicine, 2015Co-Authors: Poyi Chen, Chienming Yang, Charles M MorinAbstract:Abstract Objective The purpose of this study is to examine the factor structure of the Insomnia Severity Index (ISI) across samples recruited from different countries. We tried to identify the most appropriate factor model for the ISI and further examined the measurement invariance property of the ISI across samples from different countries. Methods Our analyses included one data set collected from a Taiwanese sample and two data sets obtained from samples in Hong Kong and Canada. The data set collected in Taiwan was analyzed with ordinal exploratory factor analysis (EFA) to obtain the appropriate factor model for the ISI. After that, we conducted a series of confirmatory factor analyses (CFAs), which is a special case of the structural equation model (SEM) that concerns the parameters in the measurement model, to the statistics collected in Canada and Hong Kong. The purposes of these CFA were to cross-validate the result obtained from EFA and further examine the cross-cultural measurement invariance of the ISI. Results The three-factor model outperforms other models in terms of global fit indices in Taiwan's population. Its external validity is also supported by confirmatory factor analyses. Furthermore, the measurement invariance analyses show that the strong invariance property between the samples from different cultures holds, providing evidence that the ISI results obtained in different cultures are comparable. Conclusions The factorial validity of the ISI is stable in different populations. More importantly, its invariance property across cultures suggests that the ISI is a valid measure of the Insomnia Severity construct across countries.
Dawn M Schiehser - One of the best experts on this subject based on the ideXlab platform.
-
psychometric characteristics of the Insomnia Severity Index in veterans with history of traumatic brain injury
Behavioral Sleep Medicine, 2019Co-Authors: Christopher N Kaufmann, Henry J Orff, Raeanne C Moore, Lisa Delanowood, Colin A Depp, Dawn M SchiehserAbstract:Objective/Background: The Insomnia Severity Index (ISI) is a widely used self-report measure of Insomnia symptoms. However, to date this measure has not been validated or well-characterized in veterans who have experienced traumatic brain injury (TBI). This study assessed the psychometric properties and convergent, divergent, construct, and discriminate validity of the ISI in veterans with a history of TBI. Participants: Eighty-three veterans with history of TBI were seen in the VA San Diego Healthcare System as part of a research protocol. Methods: Measures included the ISI, Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale, Neurobehavioral Symptom Inventory, Beck Depression Inventory-II, Beck Anxiety Inventory, and PTSD Checklist–Military Version. Results: The ISI demonstrated moderate to strong or excellent convergent and divergent validity. A principal component analysis indicated a single construct with excellent internal consistency (Cronbach’s alpha = 0.92). In exploratory analyses, t...
Christopher N Kaufmann - One of the best experts on this subject based on the ideXlab platform.
-
psychometric characteristics of the Insomnia Severity Index in veterans with history of traumatic brain injury
Behavioral Sleep Medicine, 2019Co-Authors: Christopher N Kaufmann, Henry J Orff, Raeanne C Moore, Lisa Delanowood, Colin A Depp, Dawn M SchiehserAbstract:Objective/Background: The Insomnia Severity Index (ISI) is a widely used self-report measure of Insomnia symptoms. However, to date this measure has not been validated or well-characterized in veterans who have experienced traumatic brain injury (TBI). This study assessed the psychometric properties and convergent, divergent, construct, and discriminate validity of the ISI in veterans with a history of TBI. Participants: Eighty-three veterans with history of TBI were seen in the VA San Diego Healthcare System as part of a research protocol. Methods: Measures included the ISI, Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale, Neurobehavioral Symptom Inventory, Beck Depression Inventory-II, Beck Anxiety Inventory, and PTSD Checklist–Military Version. Results: The ISI demonstrated moderate to strong or excellent convergent and divergent validity. A principal component analysis indicated a single construct with excellent internal consistency (Cronbach’s alpha = 0.92). In exploratory analyses, t...
Theodore A Omachi - One of the best experts on this subject based on the ideXlab platform.
-
measures of sleep in rheumatologic diseases epworth sleepiness scale ess functional outcome of sleep questionnaire fosq Insomnia Severity Index isi and pittsburgh sleep quality Index psqi
Arthritis Care and Research, 2011Co-Authors: Theodore A OmachiAbstract:Fatigue is a major symptom associated with rheumatologic diseases such as systemic lupus erythematosis and rheumatoid arthritis and may be a direct manifestation of disease activity, but such fatigue may also be related to sleep disturbances (1, 2). Indeed, sleep disturbances are common in a variety of rheumatologic diseases (3–5). Such disturbed sleep may be due to pain, depression, lack of exercise, or corticosteroid usage (6–8). Sleep quality may also be impaired by comorbid sleep disorders, such as obstructive sleep apnea or restless leg syndrome, the prevalences of which are reported to be high in rheumatologic populations (9–12). Sleep disturbances may, in turn, impact functional disability, lower pain thresholds, or impair immune function and thus contribute to rheumatologic-associated morbidities (13–15). Sleep disturbances in fibromyalgia and rheumatoid arthritis have received relatively more attention than in other rheumatologic diseases, but even in fibromyalgia and rheumatoid arthritis, there are many unanswered questions related to the causes and outcomes of sleep disturbances (3). The study of sleep disturbances can be onerous because gold standard direct tests, such as polysomnography and multiple sleep latency testing, are both expensive and require considerable commitment of time from research subjects. Laboratory-based sleep studies may present an additional challenge in rheumatologic populations in whom mobility restriction and pain may significantly increase subject burden. Thus, there is strong impetus for utilizing patient-reported measures in assessing sleep and sleep-related outcomes in rheumatologic diseases. Four patient-reported measures are discussed in this section, each of which captures a different sleep-related domain and has been extensively utilized in a variety of populations: [1] the Epworth Sleepiness Scale, which assesses daytime sleepiness, [2] the Functional Outcome of Sleep Questionnaire, which assesses sleep-related quality of life, [3] the Insomnia Severity Index, which measures the subjective symptoms and consequences of difficulties initiating and maintaining sleep, and [4] the Pittsburgh Sleep Quality Index, which assesses perceived sleep quality more generally. Please note that the Medical Outcomes Study Sleep Scale, a global measure of sleep quality and sleep-related outcomes, is discussed separately in this issue of Arthritis Care & Research, within the section on fibromyalgia. None of the scales reviewed here was developed specifically for rheumatologic or musculoskeletal conditions and, indeed, each has relied heavily for validation on populations with primary sleep disorders. To varying extents, as discussed below, each of these measures has been used in rheumatologic populations. Nonetheless, clinicians and researchers must carefully consider their objectives and the appropriateness of their populations in selecting a sleep questionnaire to meet their needs.
Henry J Orff - One of the best experts on this subject based on the ideXlab platform.
-
psychometric characteristics of the Insomnia Severity Index in veterans with history of traumatic brain injury
Behavioral Sleep Medicine, 2019Co-Authors: Christopher N Kaufmann, Henry J Orff, Raeanne C Moore, Lisa Delanowood, Colin A Depp, Dawn M SchiehserAbstract:Objective/Background: The Insomnia Severity Index (ISI) is a widely used self-report measure of Insomnia symptoms. However, to date this measure has not been validated or well-characterized in veterans who have experienced traumatic brain injury (TBI). This study assessed the psychometric properties and convergent, divergent, construct, and discriminate validity of the ISI in veterans with a history of TBI. Participants: Eighty-three veterans with history of TBI were seen in the VA San Diego Healthcare System as part of a research protocol. Methods: Measures included the ISI, Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale, Neurobehavioral Symptom Inventory, Beck Depression Inventory-II, Beck Anxiety Inventory, and PTSD Checklist–Military Version. Results: The ISI demonstrated moderate to strong or excellent convergent and divergent validity. A principal component analysis indicated a single construct with excellent internal consistency (Cronbach’s alpha = 0.92). In exploratory analyses, t...